Axsome Therapeutics Inc Corporate Call to Discuss the Topline Results of the INTERCEPT Trial of AXS-07 Transcript
Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I would now like to turn the conference over to your host, Mr. Mark Jacobson, Chief Operating Officer at Axsome Therapeutics. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the INTERCEPT Phase III trial of AXS-07 in the early treatment of migraine. A press release announcing that AXS-07 achieved the co-primary end points in the trial, crossed the wire a short time ago and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
